🇺🇸 FDA
Patent

US 7943318

Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer

granted A61PA61P35/00

Quick answer

US patent 7943318 (Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue May 17 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P35/00